Quarterly Result22 May 2026, 02:53 pm
Jubilant Pharmova FY26 Revenue Up 14% to ₹8,280 Cr
AI Summary
Jubilant Pharmova Ltd reported a 14% YoY increase in revenue for FY26, reaching ₹8,280 Cr, driven by growth in CDMO Sterile Injectables. EBITDA grew by 8% to ₹1,326 Cr, while Normalised PAT increased by 7% to ₹442 Cr. The board has proposed a dividend of ₹5 per equity share. Q4 FY26 revenue grew by 19% YoY to ₹2,290 Cr, and EBITDA increased by 2% to ₹363 Cr. The company experienced margin pressure due to issues at CMO Montreal but anticipates improvement in H2 FY27.
Key Highlights
- FY26 revenue grew 14% YoY to ₹8,280 Cr, driven by CDMO Sterile Injectables.
- FY26 EBITDA increased 8% YoY to ₹1,326 Cr, impacted by Radiopharmaceuticals.
- Normalised PAT for FY26 grew 7% YoY to ₹442 Cr.
- Q4 FY26 revenue increased 19% YoY to ₹2,290 Cr.
- Board proposed a dividend of ₹5 per equity share.
Price Impact
More from JUBLPHARMA